Human plasma-derived fibrinolysin (Grifols)

Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR), the first for an automated nucleic acid test (NAT) specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses. These are the four most significant arboviruses of concern, all spread through mosquito vectors. Changes in climate and increasing global connectivity have made the geographic spread of – and growing exposure to – arboviruses a major public health concern. With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1 Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA. Currently, risk for arboviruses in blood donors is evaluated either with a monoplex test, duplex test or through a questionnaire in which donors who declare having traveled to or prior residence in arbovirus-endemic areas are temporarily deferred. Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay. “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit. “Certification of this new assay provides a reliable and efficient solution to ensure accurate and consistent results, demonstrating Grifols’ continued commitment to innovating blood screening safety.” The Procleix ArboPlex Assay will be available in all markets accepting the CE mark certification after completion of any additional registration and notification requirements. About Procleix ArboPlex Assay® The Procleix ArboPlex Assay is a nucleic acid test (NAT) that uses magnetic-based target capture, Transcription-Mediated Amplification (TMA) and chemiluminescence to detect the presence of RNA sequences of four arboviruses (chikungunya virus, dengue virus RNA, West Nile virus RNA, and Zika virus) in plasma and serum from human donors. The high sensitivity and specificity of the Procleix technology enables pathogen detection to reduce the risk of transfusing infected blood or blood components, even when the donor does not exhibit symptoms. The assay runs on the widely adopted Procleix Panther System, an automated NAT instrument from Grifols. About Procleix Panther System The Procleix Panther System automates all aspects of NAT-based blood screening on a single, integrated platform, and is capable of delivering the highest result throughput per square meter. It eliminates the need for batch processing and combines walk-away freedom with intuitive design for ease of use. For more information, please visit . About Grifols Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries. Patient needs and Grifols’ ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world’s largest with over 390 across North America, Europe, Africa and the Middle East and China. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care. Grifols, with more than 23,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership. In 2023, Grifols’ economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced. The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS). For more information, please visit: MEDIA CONTACT: Media Press Office media@grifols.com Tel. +34 93 571 00 02 INVESTORS: Investors Relations Department & Sustainability inversores@grifols.com – investors@grifols.com Tel. +34 93 571 02 21 LEGAL DISCLAIMER The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group. ________________________ ¹ accessed March 2024

Company Bids Fond Farewell to Former OCA CEO Nacho AbiaRichard Reynolds, President of Medical Systems Group, to Join OCA Board CENTER VALLEY, Pa., March 27, 2024 /PRNewswire/ -- Olympus, a leading global MedTech company providing innovative solutions for medical and surgical procedures, announced today the appointment of Julien Sauvagnargues to the role of President and Chief Executive Officer (CEO), Olympus Corporation of the Americas (OCA), reporting to Olympus Chief Strategy Officer (CSO), Gabriela Kaynor, effective April 1, 2024. Continue Reading Julien Sauvagnargues This new step in Mr. Sauvagnargues' career at Olympus, which began in 2006, builds upon his tenure as OCA President since 2020. He will be responsible for overseeing Olympus' activities throughout North and South America from OCA's headquarters in Center Valley, Pennsylvania. As CEO, he will join the Board of Directors for AdvaMed, a prominent MedTech trade association. Recently, he participated in AdvaMed's CEO summit, which annually gathers the leading executives in the MedTech industry. Regionally, he continues to serve on the Board of Directors for the Lehigh Valley Partnership, a consortium of business executives and government leaders. An additional change in OCA leadership will occur as Richard Reynolds, President of the Medical Systems Group, will join the OCA Board of Directors, the regional governing body committed to the regional business, customers, and employees. In addition, after serving as Deputy General Counsel, David Gomez will assume the role of Corporate General Counsel, OCA, which was previously held by Thomas Glavin, who will retire later this year after nearly eight years at Olympus. Mr. Glavin came to Olympus in 2016 in a consultant role and became the OCA Chief Compliance Officer that same year. In February 2021, he became OCA General Counsel to oversee that region's legal function. These leadership changes are in part due to the departure from Olympus of Nacho Abia, former OCA CEO and global CSO. "Julien, Richard and I have worked closely as leaders to help make the North American Olympus business what it is today, the largest contributing region to our global revenue," said Mr. Abia. "Although I'm excited for my next journey, I'm looking forward to watching their success as they take OCA to inspiring new places." Mr. Abia has accepted the position of CEO for Grifols, a pharmaceutical company based in Barcelona, Spain, Mr. Abia's original home. His last day at Olympus is March 31, 2024. Mr. Abia was the first employee of Olympus Spain, currently known as Olympus Iberia. In 2011, he moved to Center Valley, Pennsylvania to join OCA and assumed the responsibility of President for its Consumer Imaging Business Division. In 2013, he was promoted to the role of President of OCA and in March 2015 was also appointed as its CEO. In 2020, he was promoted from President of the OCA region to take on global leadership roles as an Executive Officer and Chief Operating Officer of Olympus Corporation. He was also a member of OCA's Board of Directors and of the Global Executive Committee of Olympus in Tokyo. Mr. Abia has been pivotal in leading the business in the company's largest market in terms of sales, setting strategic direction, optimizing the company's business portfolio, and guiding the direction for future innovation. "We cannot be grateful enough for Nacho's 23-year tenure with this company," said Stefan Kaufmann, CEO, Olympus Corporation. "We will miss him greatly, but also we're delighted that Julien will take the reins for the many exciting initiatives to come." About Olympus At Olympus, we are committed to our purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals striving to provide best-in-class solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more information, visit medical.olympusamerica.com. SOURCE Olympus Corporation of the Americas